Orally Disintegrating Tablet Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

Description

The global Orally Disintegrating Tablet (ODT) market is on the verge of a significant transformation by the year 2031. The oral route of drug administration has long been the cornerstone of the pharmaceutical industry, owing to its cost-effectiveness, ease of use, and safety. While traditional tablets are typically ingested with water, ODTs are solid dosage forms that rapidly dissolve in the mouth, eliminating the need for water during administration. This innovative approach is gaining traction as a preferred alternative to traditional tablets and capsules.

The ODT Advantage:

Orally disintegrating tablets are gaining prominence for several reasons:

Increased Adoption: ODTs have witnessed growing adoption due to enhanced patient compliance. These tablets dissolve in the mouth within minutes, offering a convenient solution for those who struggle with swallowing traditional medications, such as infants, young children, and the elderly. ODTs with improved taste and rapid disintegration are further bolstering their adoption.
Enhanced Drug Bioavailability: One of the key advantages of ODTs is their ability to improve drug bioavailability. When drugs are taken orally, their concentration is significantly reduced before they reach the bloodstream due to first-pass metabolism. ODTs circumvent this issue, making them an ideal choice for delivering high molecular weight medicines, including protein and peptide-based therapies.
Rise in Clinical Trials: The popularity of ODTs has surged in recent years, driven in part by a substantial increase in clinical trials and clinical research. This has led to greater investments in the development of high-quality orally disintegrating tablets, paving the way for future market growth.

Competitive Landscape:

The Orally Disintegrating Tablet market is characterized by its high fragmentation and features a mix of established and emerging players. Market participants are actively engaged in the discovery of New Chemical Entities (NCEs) and excipients for rare diseases, as well as the development of novel formulations aimed at extending patent regimes.

Key Companies Driving Innovation:

Teva Pharmaceutical Industries Ltd.
Novartis AG
AstraZeneca
Mylan N.V.
Pfizer Inc.
Johnson & Johnson Services, Inc.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bausch Health
GlaxoSmithKline plc.
Sun Pharmaceutical Industries Ltd.
Bayer AG
Eli Lilly and Company
Dr. Reddy's Laboratories Ltd.
Takeda Pharmaceutical Company Limited

The Orally Disintegrating Tablet market is poised to redefine drug delivery methods and enhance patient experiences. As innovation continues to drive this sector forward, it promises to play a pivotal role in the pharmaceutical industry's pursuit of safer, more efficient, and patient-friendly medications.

Orally Disintegrating Tablet Market Segmentation

Orally Disintegrating Tablet Market By Drug Class

Anti-Psychotics
Anti-Epileptics
CNS Stimulants
Anxiolytics
Anti-Parkinsonian Drugs
Anti-Hypertensives
NSAIDS
Anti-Allergy Drugs
Proton Pump Inhibitors
Others

Orally Disintegrating Tablet Market By Disease Indication

CNS Diseases
GI Diseases
CVS Disorders
Allergy
Others

Orally Disintegrating Tablet Market By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

Orally Disintegrating Tablet Market By Region

North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)

1. Executive Summary

1.1. Global Orally Disintegrating Tablet Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Orally Disintegrating Tablet Market Outlook, 2018 - 2031

3.1. Global Orally Disintegrating Tablet Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Anti-Psychotics
  - 3.1.1.2. Anti-Epileptics
  - 3.1.1.3. CNS Stimulants
  - 3.1.1.4. Anxiolytics
  - 3.1.1.5. Anti-Parkinsonian Drugs
  - 3.1.1.6. Anti-Hypertensives
  - 3.1.1.7. NSAIDS
  - 3.1.1.8. Anti-Allergy Drugs
  - 3.1.1.9. Proton Pump Inhibitors
  - 3.1.1.10. Others
3.2. Global Orally Disintegrating Tablet Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. CNS Diseases
  - 3.2.1.2. GI Diseases
  - 3.2.1.3. CVS Disorders
  - 3.2.1.4. Allergy
  - 3.2.1.5. Others
3.3. Global Orally Disintegrating Tablet Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospital Pharmacies
  - 3.3.1.2. Retail Pharmacies
  - 3.3.1.3. Drug Stores
  - 3.3.1.4. Online Pharmacies
3.4. Global Orally Disintegrating Tablet Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Orally Disintegrating Tablet Market Outlook, 2018 - 2031

4.1. North America Orally Disintegrating Tablet Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Anti-Psychotics
  - 4.1.1.2. Anti-Epileptics
  - 4.1.1.3. CNS Stimulants
  - 4.1.1.4. Anxiolytics
  - 4.1.1.5. Anti-Parkinsonian Drugs
  - 4.1.1.6. Anti-Hypertensives
  - 4.1.1.7. NSAIDS
  - 4.1.1.8. Anti-Allergy Drugs
  - 4.1.1.9. Proton Pump Inhibitors
  - 4.1.1.10. Others
4.2. North America Orally Disintegrating Tablet Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. CNS Diseases
  - 4.2.1.2. GI Diseases
  - 4.2.1.3. CVS Disorders
  - 4.2.1.4. Allergy
  - 4.2.1.5. Others
4.3. North America Orally Disintegrating Tablet Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospital Pharmacies
  - 4.3.1.2. Retail Pharmacies
  - 4.3.1.3. Drug Stores
  - 4.3.1.4. Online Pharmacies
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Orally Disintegrating Tablet Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Orally Disintegrating Tablet Market Outlook, 2018 - 2031

5.1. Europe Orally Disintegrating Tablet Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Anti-Psychotics
  - 5.1.1.2. Anti-Epileptics
  - 5.1.1.3. CNS Stimulants
  - 5.1.1.4. Anxiolytics
  - 5.1.1.5. Anti-Parkinsonian Drugs
  - 5.1.1.6. Anti-Hypertensives
  - 5.1.1.7. NSAIDS
  - 5.1.1.8. Anti-Allergy Drugs
  - 5.1.1.9. Proton Pump Inhibitors
  - 5.1.1.10. Others
5.2. Europe Orally Disintegrating Tablet Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. CNS Diseases
  - 5.2.1.2. GI Diseases
  - 5.2.1.3. CVS Disorders
  - 5.2.1.4. Allergy
  - 5.2.1.5. Others
5.3. Europe Orally Disintegrating Tablet Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospital Pharmacies
  - 5.3.1.2. Retail Pharmacies
  - 5.3.1.3. Drug Stores
  - 5.3.1.4. Online Pharmacies
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Orally Disintegrating Tablet Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Orally Disintegrating Tablet Market Outlook, 2018 - 2031

6.1. Asia Pacific Orally Disintegrating Tablet Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Anti-Psychotics
  - 6.1.1.2. Anti-Epileptics
  - 6.1.1.3. CNS Stimulants
  - 6.1.1.4. Anxiolytics
  - 6.1.1.5. Anti-Parkinsonian Drugs
  - 6.1.1.6. Anti-Hypertensives
  - 6.1.1.7. NSAIDS
  - 6.1.1.8. Anti-Allergy Drugs
  - 6.1.1.9. Proton Pump Inhibitors
  - 6.1.1.10. Others
6.2. Asia Pacific Orally Disintegrating Tablet Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. CNS Diseases
  - 6.2.1.2. GI Diseases
  - 6.2.1.3. CVS Disorders
  - 6.2.1.4. Allergy
  - 6.2.1.5. Others
6.3. Asia Pacific Orally Disintegrating Tablet Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospital Pharmacies
  - 6.3.1.2. Retail Pharmacies
  - 6.3.1.3. Drug Stores
  - 6.3.1.4. Online Pharmacies
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Orally Disintegrating Tablet Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Orally Disintegrating Tablet Market Outlook, 2018 - 2031

7.1. Latin America Orally Disintegrating Tablet Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Anti-Psychotics
  - 7.1.1.2. Anti-Epileptics
  - 7.1.1.3. CNS Stimulants
  - 7.1.1.4. Anxiolytics
  - 7.1.1.5. Anti-Parkinsonian Drugs
  - 7.1.1.6. Anti-Hypertensives
  - 7.1.1.7. NSAIDS
  - 7.1.1.8. Anti-Allergy Drugs
  - 7.1.1.9. Proton Pump Inhibitors
  - 7.1.1.10. Others
7.2. Latin America Orally Disintegrating Tablet Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
7.3. Latin America Orally Disintegrating Tablet Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospital Pharmacies
  - 7.3.1.2. Retail Pharmacies
  - 7.3.1.3. Drug Stores
  - 7.3.1.4. Online Pharmacies
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Orally Disintegrating Tablet Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Orally Disintegrating Tablet Market Outlook, 2018 - 2031

8.1. Middle East & Africa Orally Disintegrating Tablet Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Anti-Psychotics
  - 8.1.1.2. Anti-Epileptics
  - 8.1.1.3. CNS Stimulants
  - 8.1.1.4. Anxiolytics
  - 8.1.1.5. Anti-Parkinsonian Drugs
  - 8.1.1.6. Anti-Hypertensives
  - 8.1.1.7. NSAIDS
  - 8.1.1.8. Anti-Allergy Drugs
  - 8.1.1.9. Proton Pump Inhibitors
  - 8.1.1.10. Others
8.2. Middle East & Africa Orally Disintegrating Tablet Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. CNS Diseases
  - 8.2.1.2. GI Diseases
  - 8.2.1.3. CVS Disorders
  - 8.2.1.4. Allergy
  - 8.2.1.5. Others
8.3. Middle East & Africa Orally Disintegrating Tablet Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospital Pharmacies
  - 8.3.1.2. Retail Pharmacies
  - 8.3.1.3. Drug Stores
  - 8.3.1.4. Online Pharmacies
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Orally Disintegrating Tablet Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Orally Disintegrating Tablet Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Orally Disintegrating Tablet Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Orally Disintegrating Tablet Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Distribution Channel vs by Disease Indication Heat map
9.2. Manufacturer vs by Disease Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Teva Pharmaceutical Industries Ltd.
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Novartis AG
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. AstraZeneca
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Mylan N.V.
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Pfizer Inc.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Johnson & Johnson Services, Inc.
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. F. Hoffmann-La Roche Ltd.
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Merck & Co., Inc.
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Bausch Health
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. GlaxoSmithKline plc.
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations